Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Get Free Report) fell 2.8% on Friday . The stock traded as low as $18.48 and last traded at $18.48. 7,254 shares traded hands during trading, a decline of 98% from the average session volume of 383,816 shares. The stock had previously closed at $19.01. Wall Street Analysts […]
/PRNewswire/ Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies.
ViroCell Biologics: ViroCell to present at 2024 Cell & Gene Meeting on the Med finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.